BG Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
BG is not a strong buy right now for a beginner long-term investor with $50,000-$100,000 who is impatient and wants a clear entry. The stock has supportive analyst sentiment and positive longer-term theme exposure, but the current technical setup is mixed, recent earnings quality weakened, and there is no proprietary buy signal today. Best call: hold rather than buy immediately.
BG closed at 123.75 and is sitting just above S1 support at 122.789, but below the pivot at 127.346. Short-term moving averages are bullish (SMA_5 > SMA_20 > SMA_200), which supports the broader trend, yet MACD histogram is negative and expanding, showing momentum is weakening. RSI_6 at 40.791 is neutral-to-soft, not oversold enough to signal an attractive immediate entry. Overall, the trend is constructive but not strong enough to justify a decisive buy today.
Analyst sentiment remains positive, with Barclays, JPMorgan, BofA, BMO, and Morgan Stanley all raising price targets and keeping Overweight/Buy-type ratings. The latest analyst notes highlight improving ag products conditions, tighter oilseed balances, and biofuel/feedstock tailwinds. Similar-pattern trend data also suggests modest near-term upside over the next month. No recent negative insider or hedge fund trends were reported, and proprietary signals are currently neutral, not bearish.
The latest quarter showed very strong revenue growth, but profitability weakened sharply: net income, EPS, and gross margin all declined year over year. That signals the business is growing top line but not converting it into stronger earnings right now. Technically, MACD is negative and expanding, which points to fading momentum. There is also no AI Stock Picker or SwingMax trigger today, reducing urgency to buy.
In 2026/Q1, BG reported revenue of $21.861 billion, up 87.76% year over year, which is a strong top-line increase. However, net income fell to $68 million, down 66.17% YoY, EPS dropped to $0.35, down 76.35% YoY, and gross margin slipped to 3.5%, down 31.77% YoY. This means the latest quarter was strong on scale but weak on earnings quality and margin performance.
Analyst sentiment has been steadily bullish. Barclays raised its target from $145 to $150 and kept Overweight, after earlier raising it from $135 to $145. JPMorgan lifted its target to $134, BofA to $130, BMO to $135, and Morgan Stanley to $140, all with positive ratings. Wall Street pros are broadly constructive on Bunge due to oilseed, crush margin, and biofuel policy tailwinds, but the recent financial results show the company still needs better margin conversion to fully justify aggressive buying.
